At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SVRA Savara Inc
Market Closed 03-21 16:00:00 EDT
2.82
-0.04
-1.40%
盘后2.86
+0.04+1.42%
19:33 EDT
| High2.92 | Low2.69 | Vol4.84M |
| Open2.92 | D1 Closing2.86 | Amplitude8.22% |
| Mkt Cap483.97M | Tradable Cap315.84M | Total Shares171.62M |
| T/O13.65M | T/O Rate4.33% | Tradable Shares112.00M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Savara Inc expected to post a loss of 11 cents a share - Earnings Preview
Reuters · 03-21 12:01
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
Business Wire · 03-17
Savara Inc expected to post a loss of 11 cents a share - Earnings Preview
Reuters · 03-10
Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell
MT Newswires Live · 03-06
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire · 03-06
Savara Inc expected to post a loss of 11 cents a share - Earnings Preview
Reuters · 03-05
Savara Announces Participation in the Leerink Global Healthcare Conference
Business Wire · 03-03
Mastek In Receipt Of Administrative Warning Letter Issued By Securities And Exchange Board Of India
Reuters · 02-28
BUZZ-India's Mastek gains on $85 mln order wins
Reuters · 02-27
Savara Announces New Employment Inducement Grant
Business Wire · 02-14
Master Tec Announces Acceptance Of Letter Of Award From Tenaga Nasional
Reuters · 02-14
Positive Signs As Multiple Insiders Buy Savara Stock
Simply Wall St. · 02-08
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
Business Wire · 01-30
Savara Announces Participation in Upcoming Healthcare Investor Conferences
Business Wire · 01-29
Mastek Dec-Quarter Consol PAT 947.1 Mln Rupees
Reuters · 01-16
DIARY- India economic, corporate events on Jan 16
Reuters · 01-16
Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses
Simply Wall St. · 01-11
Institutional investors may adopt severe steps after Savara Inc.'s (NASDAQ:SVRA) latest 11% drop adds to a year losses
Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company
Simply Wall St. · 2024-12-29
Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target
MT Newswires Live · 2024-12-20
Savara Initiated at Overweight by Wells Fargo
Dow Jones · 2024-12-20
Introduction
Company Name.
Savara Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App